Genetic polymorphisms and drug interactions modulating CYP 2 D 6 and CYP 3 A activities have a major effect on oxycodone analgesic efficacy and safetybph
暂无分享,去创建一个
D. Hochstrasser | Y. Daali | P. Dayer | G. Hopfgartner | C. Samer | M. Wagner | C. Eap | M. Rebsamen | M. Rossier | J. Desmeules
[1] P. Dayer,et al. Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics. , 2006, Personalized medicine.
[2] P. Dayer,et al. [Genetic polymorphism and drug interactions: their importance in the treatment of pain]. , 2005, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[3] M. Aceto,et al. Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. , 2004, Experimental and clinical psychopharmacology.
[4] A. Somogyi,et al. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. , 1994, The Journal of pharmacology and experimental therapeutics.
[5] D. Selley,et al. Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.
[6] P. Mackenzie,et al. INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE , 2006, Drug Metabolism and Disposition.
[7] L. Lindgren,et al. Comparison of epidural morphine and oxycodone for pain after abdominal surgery. , 1997, Journal of clinical anesthesia.
[8] M. Smith,et al. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. , 1997, Pain.
[9] J. de Leon,et al. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. , 2003, Journal of clinical psychopharmacology.
[10] E. Schuetz,et al. Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein , 2002, Journal of Pharmacology and Experimental Therapeutics.
[11] D. Parker,et al. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. , 1996, Journal of pain and symptom management.
[12] E. Kharasch,et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites , 2006, Clinical pharmacology and therapeutics.
[13] F. Coluzzi,et al. Oxycodone. Pharmacological profile and clinical data in chronic pain management. , 2005, Minerva anestesiologica.
[14] I. Creese,et al. Opiate receptor binding affected differentially by opiates and opioid peptides. , 1979, European journal of pharmacology.
[15] H. Fruhstorfer,et al. Method for quantitative estimation of thermal thresholds in patients. , 1976, Journal of neurology, neurosurgery, and psychiatry.
[16] G. Tsongalis,et al. Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[17] Mellar P. Davis,et al. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy , 2003, Supportive Care in Cancer.
[18] E. Kalso,et al. Morphine, Oxycodone, Methadone and Its Enantiomers in Different Models of Nociception in the Rat , 2006, Anesthesia and analgesia.
[19] F. Nielsen,et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. , 2009, Basic & clinical pharmacology & toxicology.
[20] Mariano Serrao,et al. The lower limb flexion reflex in humans , 2005, Progress in Neurobiology.
[21] D. Hochstrasser,et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone , 2010, British journal of pharmacology.
[22] E. Cone,et al. Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. , 1983, Drug metabolism and disposition: the biological fate of chemicals.
[23] P. Neuvonen,et al. Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone , 2009, Anesthesiology.
[24] D. Hochstrasser,et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.
[25] J. Sheller,et al. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. , 1997, The Journal of pharmacology and experimental therapeutics.
[26] E. Kalso,et al. Oxycodone’s Mechanism of Action and Potency Differences after Spinal and Systemic Routes of Administration , 2007 .
[27] Y. Daali,et al. Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[28] E. Kalso,et al. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone , 1998, Clinical pharmacology and therapeutics.
[29] E. Kalso,et al. Antinociception by Spinal and Systemic Oxycodone: Why Does the Route Make a Difference?: In Vitro and In Vivo Studies in Rats , 2006, Anesthesiology.
[30] David Yarnitsky,et al. Studies of heat pain sensation in man: perception thresholds, rate of stimulus rise and reaction time , 1990, Pain.
[31] I. Hindmarch. Psychomotor function and psychoactive drugs. , 1980, British journal of clinical pharmacology.
[32] R. Moore,et al. Morphine and ibuprofen compared using the cold pressor test , 1988, Pain.
[33] Brian R. Phillips,et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[34] Y. Daali,et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.
[35] M. Kennedy,et al. PI‐44 , 2006 .
[36] A. Telenti,et al. Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity , 2004, European Journal of Clinical Pharmacology.
[37] P. Neuvonen,et al. Voriconazole drastically increases exposure to oral oxycodone , 2009, European Journal of Clinical Pharmacology.
[38] J. Kamei,et al. Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice. , 2007, European journal of pharmacology.
[39] D. Flockhart,et al. Visual Hallucination and Tremor Induced by Sertraline and Oxycodone in a Bone Marrow Transplant Patient , 2001, Journal of clinical pharmacology.
[40] A. Somogyi,et al. Mu receptor binding of some commonly used opioids and their metabolites. , 1991, Life sciences.
[41] R. Reder,et al. Pharmacokinetic‐pharmacodynamic relationships of controlled‐release oxycodone , 1996, Clinical pharmacology and therapeutics.
[42] E. Sellers,et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity , 1993, Clinical pharmacology and therapeutics.
[43] J. Leon,et al. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[44] A. Foster,et al. Complicated Pain Management in a CYP450 2D6 Poor Metabolizer , 2007, Pain practice : the official journal of World Institute of Pain.
[45] S. Sindrup,et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker , 2009, European Journal of Clinical Pharmacology.
[46] A. Coop,et al. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. , 2007, Journal of pharmaceutical sciences.